Cyberonics, Sorin Seek Critical Mass With Merger
This article was originally published in The Gray Sheet
The yet-to-be-named combined company is predicting big opportunities, particularly, heart failure, sleep apnea and cardiac surgery.
You may also be interested in...
Boston Scientific and Cyberonics report disappointing data on vagus nerve stimulation to treat heart failure at the European Society of Cardiology conference in Barcelona. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alter Pharma Group – including its US generics operation Milla Pharmacuticals, focused on niche injectables and solutions – has rebranded as A.forall.